```
=> b reg
FILE 'REGISTRY' ENTERED AT 14:01:48 ON 18 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   17 NOV 2008  HIGHEST RN 1073055-74-9
DICTIONARY FILE UPDATES:  17 NOV 2008  HIGHEST RN 1073055-74-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d que sta l17
L5              STR
```


```
VAR G1=O/S
REP G2=(1-3) C
VAR G3=20/22
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS E8 C  E1 N  AT   1

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  10

STEREO ATTRIBUTES: NONE
L7      1386111 SEA FILE=REGISTRY ABB=ON  PLU=ON  NC2NC2/ES
L9           12 SEA FILE=REGISTRY SUB=L7 SSS FUL L5
L13             STR
```




```
VAR G1=O/S
REP G2=(1-3) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS E8 C  E1 N  AT   1

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  11

STEREO ATTRIBUTES: NONE
L16            9 SEA FILE=REGISTRY SUB=L7 SSS FUL L13
L17           21 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L9 OR L16)
```

```
=> b hcap
FILE 'HCAPLUS' ENTERED AT 14:01:57 ON 18 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 18 Nov 2008  VOL 149 ISS 21
FILE LAST UPDATED: 17 Nov 2008  (20081117/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d bib abs hitstr l20 tot
```

L20 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:1010047 HCAPLUS
DN 145:377198
TI Preparation of 1-benzylindole-2-carboxamide derivatives for the treatment of obesity or nicotine dependence
IN Cowley, Phillip Martin; Gibson, Samuel George; Wishart, Grant
PA N.V. Organon, Neth.
SO PCT Int. Appl., 65pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO--2006100208	A1	20060928	2006WO-EP060821	20060317
	WO--2006100208	A9	20071122		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	AU--2006226394	A1	20060928	2006AU-000226394	20060317
	CA-----2599855	A1	20060928	2006CA-002599855	20060317
	EP-----1940788	A1	20080709	2006EP-000725123	20060317
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, YU				
	JP--2008533187	T	20080821	2008JP-000502383	20060317
	NO--2007004441	A	20071207	2007NO-000004441	20070903
	MX---200711366	A	20071003	2007MX-000011366	20070914
	IN---200704142	A	20071116	2007IN-000004142	20070920
	CN---101151246	A	20080326	2006CN-080010701	20070929
	KR--2007121757	A	20071227	2007KR-000723732	20071016
	US-20080280923	A1	20081113	2008US-000908640	20080418
PRAI	2005EP-000102217	A	20050321		
	2006WO-EP060821	W	20060317		

OS CASREACT 145:377198; MARPAT 145:377198
GI



I

II

AB Indole-2-carboxamides of formula I [R1, R3 = H, F; R2 = H, halo, alkyl, alkoxy, cycloalkyl, etc.; R4 = H, halo, Me, OMe, CF3; R5 = H, halo, alkyl, alkoxy, OCF3; R4R5 = CH=CHNH, CH=CHCH=N; R6 = Cl, Br, CN; R7 = alkyl, cycloalkyl, etc.] are prepared for the treatment of obesity or nicotine dependence. Thus, II was prepared, and had pIC50 value > 9 against CB1 receptor.
IT 911060-41-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzylindolecarboxamide derivs. for treatment of obesity or

L20 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
nicotine dependence)
RN 911060-41-8 HCAPLUS
CN 1H-Indole-2-carboxamide, 5-cyano-N-[[(1R,2S)-2-hydroxycyclohexyl]methyl]-1-[[3-(4-methyl-1-piperazinyl)phenyl]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:472507 HCAPLUS
DN 139:36797
TI Preparation of alanylpiperidine heterocyclic derivatives for use in the treatment of cardiovascular diseases
IN Jones, Stuart Donald; Sall, Daniel Jon; Wiley, Michael Robert
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO--2003050109	A1	20030619	2002WO-US0037595	20021209
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU--2002359458	A1	20030623	2002AU-000359458	20021209
	EP-----1456198	A1	20040915	2002EP-000793998	20021209
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	US-20040254374	A1	20041216	2004US-000496019	20040601
	US-----7115609	B2	20061003		
PRAI	2001US-00339325P	P	20011212		
	2002WO-US0037595	W	20021209		

OS MARPAT 139:36797
GI



I

AB Compds. I [X1 = CH or N; n = 1 or 2; R1 = H or Me; R1 = CF3, CO2H, CONH2, SO2NH2, Ph, pyridyl, C-linked (N-alkyl)imidazolyl, cycloalkyl, oxa-, thia- or (N-alkyl)azacycloalkyl; R2 = 4-Cl-, 4-MeO-, or 4-MeC6H4 which may be 3-substituted, 2- or 6-indolyl which may be 5- or 3-substituted, resp., or 2-benzothienyl which may be 6-substituted] or their pharmaceutically-acceptable salts were prepared as factor Xa inhibitors useful in the treatment of thrombotic disorders. Thus, 1-[N-(indole-6-carbonyl)-β-phenyl-D-alanyl]-4-(1-methylpiperidin-4-yl)piperidine hydrochloride was prepared by coupling of N-(tert-butoxycarbonyl)-β-phenyl-D-alanine with 1-(1-methylpiperidin-4-yl)piperazine, followed by deprotection and acylation with indole-6-carboxylic acid.
IT 544478-85-5P 544478-86-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of alanylpiperidine heterocyclic derivs. as factor Xa inhibitors for use in treatment of thrombotic disorders)
RN 544478-85-5 HCAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R)-1-(cyclohexylmethyl)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-, monohydrochloride (9CI)

L20 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 544478-86-6 HCAPLUS
CN 1H-Indole-6-carboxamide, N-[(1R)-1-(cyclohexylmethyl)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-, hydrochloride (10:11) (CA INDEX NAME)

Absolute stereochemistry.



●11/10 HCl

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:97413 HCAPLUS
DN 138:153555
TI Preparation of piperidinyl piperazine and piperidine derivatives as thrombolytic agents
IN Wiley, Michael Robert; Liebeschuetz, John Walter; Sall, Daniel Jon
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO--2003010160	A2	20030206	2002WO-US021292	20020724
	WO--2003010160	A3	20031002		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU--2002322396	A1	20030217	2002AU-000322396	20020724
	EP-----1409479	A2	20040421	2002EP-000756385	20020724
	EP-----1409479	B1	20080123		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	AT------384713	T	20080215	2002AT-000756385	20020724
	ES-----2298386	T3	20080516	2002ES-000756385	20020724
	US-20050026928	A1	20050203	2004US-000483264	20040115
	US-----7265121	B2	20070904		
PRAI	2001US-00307634P	P	20010726		
	2001US-00311462P	P	20010813		
	2001US-00339317P	P	20011212		
	2002WO-US021292	W	20020724		

OS MARPAT 138:153555
GI



I



II

AB Piperidinyl piperazines and piperidines [I; wherein X = CH, N; R1 = (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl; R2 = (substituted) aryl,

L20 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry. Rotation (-).



IT 495377-15-6P 495377-17-8P 495377-21-4P
495377-25-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperidinyl piperazine derivs. as Factor Xa inhibitors)
RN 495377-15-6 HCAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R)-1-[[4-(1-methyl-4-piperidinyl)-1-piperazinyl]carbonyl]-3-butyn-1-yl]-, hydrochloride (10:9) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



●9/10 HCl

RN 495377-17-8 HCAPLUS
CN 1H-Indole-6-carboxamide, N-[(1R)-1-[[4-(1-methyl-4-piperidinyl)-1-piperazinyl]carbonyl]-3-butyn-1-yl]-, hydrochloride (5:6) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



●6/5 HCl

RN 495377-21-4 HCAPLUS
CN 1H-Indole-6-carboxamide, N-[(1R)-1-[[4-(1-methyl-4-piperidinyl)-1-piperazinyl]carbonyl]-3-buten-1-yl]-, hydrochloride (5:6) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L20 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
arenoheterocycle] were prepd. For example, compd. (II) was prepd. by the claimed methodol. The prepd. compds. are effective human Factor Xa inhibitors (Kass > 1 * 106 L/mol) and, thus, are effective as anticoagulants.
IT 495377-13-4P 495377-16-7P 495377-20-3P
495377-24-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of piperidinyl piperazine derivs. as Factor Xa inhibitors)
RN 495377-13-4 HCAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R)-1-[[4-(1-methyl-4-piperidinyl)-1-piperazinyl]carbonyl]-3-butyn-1-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 495377-16-7 HCAPLUS
CN 1H-Indole-6-carboxamide, N-[(1R)-1-[[4-(1-methyl-4-piperidinyl)-1-piperazinyl]carbonyl]-3-butyn-1-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 495377-20-3 HCAPLUS
CN 1H-Indole-6-carboxamide, N-[(1R)-1-[[4-(1-methyl-4-piperidinyl)-1-piperazinyl]carbonyl]-3-buten-1-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 495377-24-7 HCAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R)-1-[[4-(1-methyl-4-piperidinyl)-1-piperazinyl]carbonyl]-3-buten-1-yl]- (CA INDEX NAME)

L20 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



●6/5 HCl

RN 495377-25-8 HCAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R)-1-[[4-(1-methyl-4-piperidinyl)-1-piperazinyl]carbonyl]-3-buten-1-yl]-, hydrochloride (10:11) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



●11/10 HCl

L20 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 2002:658115 HCAPLUS
DN 137:201342
TI Preparation of heterocyclic amides as dopamine D3 receptors for treating central nervous system disorders
IN Hendrix, James A.; Strupczewski, Joseph T.; Bordeau, Kenneth J.; Urmann, Matthias; Shutske, Gregory; Hemmerle, Horst; Jurcak, John G.; Gill, Harpal; Weiberth, Franz, Jr.; Niedzak, Thaddeus; Jackson, Sharon A.; Zhao, Xu-Yang; Mueller, Paul J.
PA Aventis Pharmaceuticals Inc., USA
SO PCT Int. Appl., 355 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2002066469	A2	20020829	2002WO-US0004917	20020215
WO--2002066469	A3	20030313		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA-----2438318	A1	20020829	2002CA-002438318	20020215
AU--2002252009	A1	20020904	2002AU-000252009	20020215
EP-----1361875	A2	20031119	2002EP-000721057	20020215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP--2004518745	T	20040624	2002JP-000565983	20020215
EP-----1688412	A2	20060809	2006EP-000007084	20020215
EP-----1688412	A3	20060816		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
US-20040030137	A1	20040212	2002US-000078206	20020219
MX-2003PA06524	A	20030925	2003MX-PA0006524	20030722
US-20050107389	A1	20050519	2004US-000960399	20041007
US-20070142351	A1	20070621	2006US-000643594	20061221
AU--2008202190	A1	20080605	2008AU-000202190	20080516
PRAI 2001US-0026923P	P	20010216		
2001GB-000017531	A	20010719		
2002AU-000252009	A3	20020215		
2002EP-000721057	A3	20020215		
2002WO-US0004917	W	20020215		
2002US-000078206	B1	20020219		
2004US-000960399	B1	20041007		

OS MARPAT 137:201342
GI

L20 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB The title benzothiophenes, diazepines, piperazines, and thienoisoxazoles with general formula I [wherein Y = CO, SO2, or a bond; A = CH or N; n = 1-2; p = 0 or 2; m = 0-2; R3 = H or (phenyl)alkyl; R = specified (un)substituted (hetero)aryl; B = (un)substituted (cyclo)alkylene, alkenylene, etc.; R1 = H, (un)substituted alkyl, or (un)substituted arylalkyl; R2 = alkyl, CF3, specified (un)substituted (hetero)aryl(alkyl), (hetero)cyclyl(alkyl), etc.; and pharmaceutically acceptable salts thereof] were prepared For example, reaction of 4-[4-(6-fluorobenzo[b]thiophen-3-yl)-[1,4]diazepan-1-yl]butylamine (preparation given) and indole-2-carboxylic acid gave the amide II. I displayed selective binding to dopamine D3 receptors with Ki values in the range of 0.12 nM to 871 nM. The invention also relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity, including psychotic disorders, substance dependence, substance abuse, dyskinetic disorders (e.g. Parkinson's disease, neuroleptic-induced tardive dyskinesia, Gilles de la Tourette syndrome, and Huntington's disease), dementia, anxiety disorders, sleep disorders, circadian rhythm disorders, and mood disorders. Methods using radiolabeled I for single photon emission computed tomog. are also disclosed.

IT 453539-59-8P 453539-60-1P 453541-86-1P
453541-87-2P 453541-88-3P 453541-89-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(inhibitor; preparation of heterocyclic amides as dopamine D3 receptors for treating central nervous system disorders)

RN 453539-59-8 HCAPLUS
CN 1H-Indole-2-carboxamide, 5-methoxy-N-[[(1R,2R)-2-[[4-[6-(trifluoromethyl)benzo[b]thien-3-yl]-1-piperazinyl]methyl]cyclohexyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L20 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 453539-60-1 HCAPLUS
CN 1H-Indole-2-carboxamide, N-[[(1R,2R)-2-[[4-[6-(trifluoromethyl)benzo[b]thien-3-yl]-1-piperazinyl]methyl]cyclohexyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 453541-86-1 HCAPLUS
CN 1H-Indole-2-carboxamide, N-[(2E)-4-[4-[6-(trifluoromethyl)benzo[b]thien-3-yl]-1-piperazinyl]-2-buten-1-yl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 453541-87-2 HCAPLUS
CN 1H-Indole-2-carboxamide, 5-methoxy-N-[(2E)-4-[4-[6-(trifluoromethyl)benzo[b]thien-3-yl]-1-piperazinyl]-2-buten-1-yl]- (CA INDEX NAME)

Double bond geometry as shown.

L20 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

RN 453541-88-3 HCAPLUS
CN 1H-Indole-2-carboxamide, N-[(2Z)-4-[4-[6-(trifluoromethyl)benzo[b]thien-3-yl]-1-piperazinyl]-2-buten-1-yl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 453541-89-4 HCAPLUS
CN 1H-Indole-2-carboxamide, 5-methoxy-N-[(2Z)-4-[4-[6-(trifluoromethyl)benzo[b]thien-3-yl]-1-piperazinyl]-2-buten-1-yl]- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

L20 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 2001:923784 HCAPLUS

DN 136:54020

TI Preparation of amino acid derivatives as serine protease inhibitors

IN Liebeschuetz, John Walter; Murray, Christopher William; Young, Stephen Clinton; Camp, Nicholas Paul; Jones, Stuart Donald; Wylie, William Alexander; Masters, John Joseph; Wiley, Michael Robert; Sheehan, Scott Martin; Engel, David Birenbaum; Watson, Brian Morgan; Guzzo, Peter Robert; Mayer, Michael John

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 191 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO--2001096323	A1	20011220	2001WO-GB002553	20010612
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	WO--2000076971	A2	20001221	2000WO-GB002302	20000613
	WO--2000076971	A3	20010802		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA-----2411805	A1	20011220	2001CA-002411805	20010612
	EP-----1289972	A1	20030312	2001EP-000936686	20010612
	EP-----1289972	B1	20040908		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR--2001011451	A	20030624	2001BR-000011451	20010612
	HU--2003000720	A2	20030728	2003HU-000000720	20010612
	JP--2004503547	T	20040205	2002JP-000510466	20010612
	JP-----4175885	B2	20081105		
	NZ------521896	A	20040730	2001NZ-000521896	20010612
	AT------275554	T	20040915	2001AT-000936686	20010612
	AU--2001262553	B2	20060706	2001AU-000262553	20010612
	US-20030055246	A1	20030320	2002US-000030187	20020204
	US-----6946467	B2	20050920		
	TW------257389	B	20060701	2002TW-091112134	20020605
	WO--2002100847	A2	20021219	2002WO-US0016569	20020606
	WO--2002100847	A3	20030821		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU--2002348501	A1	20021223	2002AU-000348501	20020606
	EP-----1397348	A2	20040317	2002EP-000778933	20020606
	EP-----1397348	B1	20050928		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP--2004534062	T	20041111	2003JP-000503615	20020606

L20 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

	AT------305452	T	20051015	2002AT-000778933	20020606
	ES-----2248618	T3	20060316	2002ES-000778933	20020606
	MX-2002PA11411	A	20030425	2002MX-PA0011411	20021119
	NO--2002005665	A	20021125	2002NO-000005665	20021125
	NO------324696	B1	20071203		
	HR--2002000997	B1	20050228	2002HR-000000997	20021212
	HK-----1054379	A1	20050324	2003HK-000106546	20030911
	US-20040162295	A1	20040819	2003US-000477192	20031117
	US-20040142963	A1	20040722	2004US-000754923	20040112
	US-----6936611	B2	20050830		
	US-20040176363	A1	20040909	2004US-000803157	20040318
	US-----7351822	B2	20080401		

PRAI 2000WO-GB002302 W 20000613
2000GB-000030304 A 20001213
1999GB-000013823 A 19990614
1999US-00142064P P 19990702
1999GB-000018741 A 19990809
1999GB-000029553 A 19991214
2001WO-GB0002553 W 20010612
2001US-00339295P P 20011212
2002US-000030187 A1 20020204
2002WO-US0016569 W 20020606

OS MARPAT 136:54020

AB Compds. R2-X-X-Y(Cy)-L-Lp(D)n [R2 is a 5- or 6-membered aromatic carbon ring optionally interrupted by a N, O or S ring atom, optionally substituted at the 3 and/or 4 position or forms a fused ring system at these positions, which is an optionally substituted 5- or 6-membered carbocyclic or heterocyclic ring, or substituted at the position alpha to X-X, with the proviso that R2 can not be aminoisoquinolyl; X is a C, N, O or S atom or a CO, CR1a, C(R1a)2 or NR1a group [at least one X is C, CO, CR1a or C(R1a)2], where R1a represents H, OH, alkoxy, alkyl, aminoalkyl, hydroxyalkyl, alkoxyalkyl, alkoxycarbonyl, alkylaminocarbonyl, alkoxycarbonylamino, acyloxymethoxycarbonyl or alkylamino optionally substituted by OH, alkylamino, alkoxy, oxo, aryl or cycloalkyl; Y is a N atom or a CR1b group (R1b defined as for R1a); Cy is an (un)substituted, (un)saturated, mono- or polycyclic, homo- or heterocyclic group; -L-Lp(D)n is 4-substituted 1-piperazinecarbonyl] or their physiol.-tolerable salts were prepared for use as serine protease inhibitors. Compds. of the invention were found to significantly elongate the partial thromboplastin time (prothrombin time). Thus, 1-(4-methoxybenzoyl-D-phenylglycinyl)-4-phenethylpiperazine was prepared in the first of 82 examples.

IT 381721-26-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid derivs. as serine protease inhibitors)

RN 381721-26-2 HCAPLUS

CN 1H-Indole-6-carboxamide, N-[(1R)-1-cyclohexyl-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

L20 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> b uspatall
FILE 'USPATFULL' ENTERED AT 14:02:08 ON 18 NOV 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 14:02:08 ON 18 NOV 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:02:08 ON 18 NOV 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitstr l21 tot
```

L21 ANSWER 1 OF 7 USPATFULL on STN
AN 2007:162795 USPATFULL
TI Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands
IN Hendrix, James A., Hillsborough, NJ, UNITED STATES
Strupczewski, Joseph T., Flemington, NJ, UNITED STATES
Bordeau, Kenneth J., Kintnersville, PA, UNITED STATES
Urmann, Matthias, Eschborn, GERMANY, FEDERAL REPUBLIC OF
Shutske, Gregory, Pittstown, NJ, UNITED STATES
Hemmerle, Horst, Indianapolis, IN, UNITED STATES
Jurcak, John G., Bethlehem, PA, UNITED STATES
Gill, Harpal, West Chester, OH, UNITED STATES
Weiberth, Franz J., Ringoes, NJ, UNITED STATES
Nieduzak, Thaddeus R., Bridgewater, NJ, UNITED STATES
Jackson, Sharon Anne, Whitehouse Station, NJ, UNITED STATES
Zhao, Xu-Yang, Bridgewater, NJ, UNITED STATES
Mueller, Paul Justin, Hoboken, NJ, UNITED STATES
PA Aventis Pharmaceuticals Inc., Bridgewater, NJ, UNITED STATES (U.S. corporation)
PI US-20070142351 A1 20070621
AI 2006US-000643594 A1 20061221 (11)
RLI Continuation of Ser. No. 2004US-000960399, filed on 7 Oct 2004, ABANDONED
PRAI 2001GB-000017531 20010719
DT Utility
FS APPLICATION
LREP ROSS J. OEHLER, SANOFI-AVENTIS U.S. LLC, 1041 ROUTE 202-206, MAIL CODE: D303A, BRIDGEWATER, NJ, 08807, US
CLMN Number of Claims: 39
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5519
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to heterocyclic substituted amide derivatives that display selective binding to dopamine D.sub.3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D.sub.3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D.sub.3 receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 453539-59-8P 453539-60-1P 453541-86-1P
453541-87-2P 453541-88-3P 453541-89-4P
(inhibitor; preparation of heterocyclic amides as dopamine D3 receptors for treating central nervous system disorders)
RN 453539-59-8 USPATFULL
CN 1H-Indole-2-carboxamide, 5-methoxy-N-[[(1R,2R)-2-[[4-(6-(trifluoromethyl)benzo[b]thien-3-yl]-1-piperazinyl]methyl]cyclohexyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L21 ANSWER 1 OF 7 USPATFULL on STN (Continued)
Double bond geometry as shown.



RN 453541-88-3 USPATFULL
CN 1H-Indole-2-carboxamide, N-[(2Z)-4-[4-[6-(trifluoromethyl)benzo[b]thien-3-yl]-1-piperazinyl]-2-buten-1-yl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 453541-89-4 USPATFULL
CN 1H-Indole-2-carboxamide, 5-methoxy-N-[(2Z)-4-[4-[6-(trifluoromethyl)benzo[b]thien-3-yl]-1-piperazinyl]-2-buten-1-yl]- (CA INDEX NAME)

Double bond geometry as shown.



L21 ANSWER 1 OF 7 USPATFULL on STN (Continued)



RN 453539-60-1 USPATFULL
CN 1H-Indole-2-carboxamide, N-[[(1R,2R)-2-[[4-(6-(trifluoromethyl)benzo[b]thien-3-yl]-1-piperazinyl]methyl]cyclohexyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 453541-86-1 USPATFULL
CN 1H-Indole-2-carboxamide, N-[(2E)-4-[4-[6-(trifluoromethyl)benzo[b]thien-3-yl]-1-piperazinyl]-2-buten-1-yl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 453541-87-2 USPATFULL
CN 1H-Indole-2-carboxamide, 5-methoxy-N-[(2E)-4-[4-[6-(trifluoromethyl)benzo[b]thien-3-yl]-1-piperazinyl]-2-buten-1-yl]- (CA INDEX NAME)

L21 ANSWER 2 OF 7 USPATFULL on STN
AN 2005:124999 USPATFULL
TI Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands
IN Hendrix, James A., Hillsborough, NJ, UNITED STATES
Strupczeski, Joseph T., Flemington, NJ, UNITED STATES
Bordeau, Kenneth J., Kintnersville, PA, UNITED STATES
Urmann, Matthias, Eschborn, GERMANY, FEDERAL REPUBLIC OF
Shutske, Gregory, Pittstown, NJ, UNITED STATES
Hemmerle, Horst, Noblesville, IN, UNITED STATES
Jurcak, John G., Bethlehem, PA, UNITED STATES
Gill, Harpal, West Chester, OH, UNITED STATES
Weiberth, Franz J., Ringoes, NJ, UNITED STATES
Nieduzak, Thaddeus R., Bridgewater, NJ, UNITED STATES
Jackson, Sharon Anne, Whitehouse, NJ, UNITED STATES
Zhao, Xu-Yang, Bridgewater, NJ, UNITED STATES
Mueller, Paul Justin, Hoboken, NJ, UNITED STATES
PA Aventis Pharmaceuticals Inc., Bridgewater, NJ, UNITED STATES (U.S. corporation)
PI US-20050107389 A1 20050519
AI 2004US-000960399 A1 20041007 (10)
RLI Continuation of Ser. No. 2002US-000078206, filed on 19 Feb 2002, ABANDONED
PRAI 2001GB-000017531 20010719
2001US-000269253P 20010216 (60)
DT Utility
FS APPLICATION
LREP ROSS J. OEHLER, AVENTIS PHARMACEUTICALS INC., ROUTE 202-206, MAIL CODE: D303A, BRIDGEWATER, NJ, 08807, US
CLMN Number of Claims: 73
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5951
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to heterocyclic substituted amide derivatives that display selective binding to dopamine D.sub.3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D.sub.3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D.sub.3 receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 453539-59-8P 453539-60-1P 453541-86-1P
453541-87-2P 453541-88-3P 453541-89-4P
(inhibitor; preparation of heterocyclic amides as dopamine D3 receptors for treating central nervous system disorders)
RN 453539-59-8 USPATFULL
CN 1H-Indole-2-carboxamide, 5-methoxy-N-[[(1R,2R)-2-[[4-(6-(trifluoromethyl)benzo[b]thien-3-yl]-1-piperazinyl]methyl]cyclohexyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L21 ANSWER 2 OF 7 USPATFULL on STN (Continued)



RN 453539-60-1 USPATFULL
CN 1H-Indole-2-carboxamide, N-[[(1R,2R)-2-[[4-[6-(trifluoromethyl)benzo[b]thien-3-yl]-1-piperazinyl]methyl]cyclohexyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 453541-86-1 USPATFULL
CN 1H-Indole-2-carboxamide, N-[(2E)-4-[4-[6-(trifluoromethyl)benzo[b]thien-3-yl]-1-piperazinyl]-2-buten-1-yl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 453541-87-2 USPATFULL
CN 1H-Indole-2-carboxamide, 5-methoxy-N-[(2E)-4-[4-[6-(trifluoromethyl)benzo[b]thien-3-yl]-1-piperazinyl]-2-buten-1-yl]- (CA INDEX NAME)

L21 ANSWER 2 OF 7 USPATFULL on STN (Continued)

PAGE 1-B

L21 ANSWER 2 OF 7 USPATFULL on STN (Continued)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 453541-88-3 USPATFULL
CN 1H-Indole-2-carboxamide, N-[(2Z)-4-[4-[6-(trifluoromethyl)benzo[b]thien-3-yl]-1-piperazinyl]-2-buten-1-yl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 453541-89-4 USPATFULL
CN 1H-Indole-2-carboxamide, 5-methoxy-N-[(2Z)-4-[4-[6-(trifluoromethyl)benzo[b]thien-3-yl]-1-piperazinyl]-2-buten-1-yl]- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



L21 ANSWER 3 OF 7 USPATFULL on STN
AN 2005:31491 USPATFULL
TI Chemical compounds
IN Wiley, Michael Robert, Indianapolis, IN, UNITED STATES
Sall, Daniel Jon, Greenwood, IN, UNITED STATES
Liebeschuetz, John Walter, Bollington, UNITED KINGDOM
PI US-20050026928 A1 20050203
US-----7265121 B2 20070904
AI 2004US-000483264 A1 20040115 (10)
2002WO-US0021292 20020724
PRAI 2001US-000307634P 20010726 (60)
2001US-000311462P 20010813 (60)
2001US-000339317P 20011212 (60)
DT Utility
FS APPLICATION
LREP Martin A. Hay, 13 Queen Victoria Street, Macclesfield Cheshire UK, SK11 6LP
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1782
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I) ##STR1##

in which R.sup.1, R.sup.2 and X.sup.4 have the meanings given in the specification are Factor Xa inhibitors useful in the treatment of thrombotic disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 495377-13-4P 495377-16-7P 495377-20-3P
495377-24-7P
(preparation of piperidinyl piperazine derivs. as Factor Xa inhibitors)
RN 495377-13-4 USPATFULL
CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R)-1-[[4-(1-methyl-4-piperidinyl)-1-piperazinyl]carbonyl]-3-butyn-1-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 495377-16-7 USPATFULL
CN 1H-Indole-6-carboxamide, N-[(1R)-1-[[4-(1-methyl-4-piperidinyl)-1-piperazinyl]carbonyl]-3-butyn-1-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 495377-20-3 USPATFULL
CN 1H-Indole-6-carboxamide, N-[(1R)-1-[[4-(1-methyl-4-piperidinyl)-1-piperazinyl]carbonyl]-3-buten-1-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L21 ANSWER 3 OF 7 USPATFULL on STN (Continued)



RN 495377-24-7 USPATFULL
CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R)-1-[[4-(1-methyl-4-piperidinyl)-1-piperazinyl]carbonyl]-3-buten-1-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 495377-15-6P 495377-17-8P 495377-21-4P
495377-25-8P
(preparation of piperidinyl piperazine derivs. as Factor Xa inhibitors)
RN 495377-15-6 USPATFULL
CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R)-1-[[4-(1-methyl-4-piperidinyl)-1-piperazinyl]carbonyl]-3-butyn-1-yl]-, hydrochloride (10:9) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



●9/10 HCl

RN 495377-17-8 USPATFULL
CN 1H-Indole-6-carboxamide, N-[(1R)-1-[[4-(1-methyl-4-piperidinyl)-1-piperazinyl]carbonyl]-3-butyn-1-yl]-, hydrochloride (5:6) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L21 ANSWER 3 OF 7 USPATFULL on STN (Continued)



●6/5 HCl

RN 495377-21-4 USPATFULL
CN 1H-Indole-6-carboxamide, N-[(1R)-1-[[4-(1-methyl-4-piperidinyl)-1-piperazinyl]carbonyl]-3-buten-1-yl]-, hydrochloride (5:6) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



●6/5 HCl

RN 495377-25-8 USPATFULL
CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R)-1-[[4-(1-methyl-4-piperidinyl)-1-piperazinyl]carbonyl]-3-buten-1-yl]-, hydrochloride (10:11) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



●11/10 HCl

L21 ANSWER 4 OF 7 USPATFULL on STN
AN 2004:321719 USPATFULL
TI Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases
IN Jones, Stuart Donald, Macclesfield, UNITED KINGDOM
Sall, Daniel Jon, Greenwood, IN, UNITED STATES
Wiley, Michael Robert, Indianapolis, IN, UNITED STATES
PI US-20040254374 A1 20041216
US------7115609 B2 20061003
AI 2004US-000496019 A1 20040601 (10)
2002WO-US0037595 20021209
PRAI 2001US-000339325P 20011212 (60)
DT Utility
FS APPLICATION
LREP Martin A. Hay, 13 Queen Victoria Street, Macclesfield Cheshire UK, SK11 6LP
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1834
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I) ##STR1##

in which R.sup.1, R.sup.2, n and X.sup.1 have the meanings given in the specification are Factor Xa inhibitors useful in the treatment of thrombotic disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 544478-85-5P 544478-86-6P
(preparation of alanylpiperidine heterocyclic derivs. as factor Xa inhibitors for use in treatment of thrombotic disorders)
RN 544478-85-5 USPATFULL
CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R)-1-(cyclohexylmethyl)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 544478-86-6 USPATFULL
CN 1H-Indole-6-carboxamide, N-[(1R)-1-(cyclohexylmethyl)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-, hydrochloride (10:11) (CA INDEX NAME)

Absolute stereochemistry.

L21 ANSWER 4 OF 7 USPATFULL on STN (Continued)



●11/10 HCl

L21 ANSWER 5 OF 7 USPATFULL on STN

AN 2004:39595 USPATFULL
TI Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands
IN Hendrix, James A., Hillsborough, NJ, UNITED STATES
Strupczewski, Joseph T., Flemington, NJ, UNITED STATES
Bordeau, Kenneth J., Kintnersville, PA, UNITED STATES
Urmann, Matthias, Eschborn, GERMANY, FEDERAL REPUBLIC OF
Shutske, Gregory, Pittstown, NJ, UNITED STATES
Hemmerle, Horst, Indianapolis, IN, UNITED STATES
Jurcak, John G., Bethlehem, PA, UNITED STATES
Gill, Harpal, West Chester, OH, UNITED STATES
Weiberth, Franz J., Ringoes, NJ, UNITED STATES
Nieduzak, Thaddeus R., Bridgewater, NJ, UNITED STATES
Jackson, Sharon Anne, Whitehouse Station, NJ, UNITED STATES
Zhao, Xu-Yang, Bridgewater, NJ, UNITED STATES
Mueller, Paul Justin, Hoboken, NJ, UNITED STATES
PI US-20040030137 A1 20040212
AI 2002US-000078206 A1 20020219 (10)
PRAI 2001GB-000017531 20010719
2001US-000269253P 20010216 (60)
DT Utility
FS APPLICATION
LREP ROSS J. OEHLER, AVENTIS PHARMACEUTICALS INC., ROUTE 202-206, MAIL CODE: D-303A, BRIDGEWATER, PA, 08807
CLMN Number of Claims: 73
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6107
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to heterocyclic substituted amide derivatives that display selective binding to dopamine D.sub.3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D.sub.3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D.sub.3 receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 453539-59-8P 453539-60-1P 453541-86-1P
453541-87-2P 453541-88-3P 453541-89-4P
(inhibitor; preparation of heterocyclic amides as dopamine D3 receptors for treating central nervous system disorders)
RN 453539-59-8 USPATFULL
CN 1H-Indole-2-carboxamide, 5-methoxy-N-[[(1R,2R)-2-[[4-[6-(trifluoromethyl)benzo[b]thien-3-yl]-1-piperazinyl]methyl]cyclohexyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L21 ANSWER 5 OF 7 USPATFULL on STN (Continued)

Double bond geometry as shown.

PAGE 1-A

PAGE 1-B

OMe

RN 453541-88-3 USPATFULL
CN 1H-Indole-2-carboxamide, N-[(2Z)-4-[4-[6-(trifluoromethyl)benzo[b]thien-3-yl]-1-piperazinyl]-2-buten-1-yl]- (CA INDEX NAME)

Double bond geometry as shown.

RN 453541-89-4 USPATFULL
CN 1H-Indole-2-carboxamide, 5-methoxy-N-[(2Z)-4-[4-[6-(trifluoromethyl)benzo[b]thien-3-yl]-1-piperazinyl]-2-buten-1-yl]- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A

PAGE 1-B

OMe

L21 ANSWER 5 OF 7 USPATFULL on STN (Continued)

RN 453539-60-1 USPATFULL
CN 1H-Indole-2-carboxamide, N-[[(1R,2R)-2-[[4-[6-(trifluoromethyl)benzo[b]thien-3-yl]-1-piperazinyl]methyl]cyclohexyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 453541-86-1 USPATFULL
CN 1H-Indole-2-carboxamide, N-[(2E)-4-[4-[6-(trifluoromethyl)benzo[b]thien-3-yl]-1-piperazinyl]-2-buten-1-yl]- (CA INDEX NAME)

Double bond geometry as shown.

RN 453541-87-2 USPATFULL
CN 1H-Indole-2-carboxamide, 5-methoxy-N-[(2E)-4-[4-[6-(trifluoromethyl)benzo[b]thien-3-yl]-1-piperazinyl]-2-buten-1-yl]- (CA INDEX NAME)

L21 ANSWER 6 OF 7 USPAT2 on STN

AN 2005:31491 USPAT2
TI Chemical compounds
IN Wiley, Michael Robert, Indianapolis, IN, UNITED STATES
Sall, Daniel Jon, Greenwood, IN, UNITED STATES
Liebeschuetz, John Walter, Bollington, UNITED KINGDOM
PA Eli Lilly and Company, Indianapolis, IN, UNITED STATES (U.S. corporation)
PI US-----7265121 B2 20070904
WO--2003010160 20030206
AI 2002US-000483264 20020724 (10)
2002WO-US0021292 20020724
20040115 PCT 371 date
PRAI 2001US-000339317P 20011212 (60)
2001US-000311462P 20010813 (60)
2001US-000307634P 20010726 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Chang, Celia
LREP Jackson, Thomas E.
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1718
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I)

##STR1## in which R.sup.1, R.sup.2 and X.sup.4 have the meanings given in the specification are Factor Xa inhibitors useful in the treatment of thrombotic disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 495377-13-4P 495377-16-7P 495377-20-3P
495377-24-7P
(preparation of piperidinyl piperazine derivs. as Factor Xa inhibitors)
RN 495377-13-4 USPAT2
CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R)-1-[[4-(1-methyl-4-piperidinyl)-1-piperazinyl]carbonyl]-3-butyn-1-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

RN 495377-16-7 USPAT2
CN 1H-Indole-6-carboxamide, N-[(1R)-1-[[4-(1-methyl-4-piperidinyl)-1-piperazinyl]carbonyl]-3-butyn-1-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

RN 495377-20-3 USPAT2
CN 1H-Indole-6-carboxamide, N-[(1R)-1-[[4-(1-methyl-4-piperidinyl)-1-

L21 ANSWER 6 OF 7 USPAT2 on STN (Continued)
piperazinyl]carbonyl]-3-buten-1-yl}- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 495377-24-7 USPAT2
CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R)-1-[[4-(1-methyl-4-piperidinyl)-1-piperazinyl]carbonyl]-3-buten-1-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 495377-15-6P 495377-17-8P 495377-21-4P
495377-25-8P
(preparation of piperidinyl piperazine derivs. as Factor Xa inhibitors)
RN 495377-15-6 USPAT2
CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R)-1-[[4-(1-methyl-4-piperidinyl)-1-piperazinyl]carbonyl]-3-butyn-1-yl]-, hydrochloride (10:9) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



●9/10 HCl

RN 495377-17-8 USPAT2
CN 1H-Indole-6-carboxamide, N-[(1R)-1-[[4-(1-methyl-4-piperidinyl)-1-piperazinyl]carbonyl]-3-butyn-1-yl]-, hydrochloride (5:6) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L21 ANSWER 6 OF 7 USPAT2 on STN (Continued)



●6/5 HCl

RN 495377-21-4 USPAT2
CN 1H-Indole-6-carboxamide, N-[(1R)-1-[[4-(1-methyl-4-piperidinyl)-1-piperazinyl]carbonyl]-3-buten-1-yl]-, hydrochloride (5:6) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



●6/5 HCl

RN 495377-25-8 USPAT2
CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R)-1-[[4-(1-methyl-4-piperidinyl)-1-piperazinyl]carbonyl]-3-buten-1-yl]-, hydrochloride (10:11) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



●11/10 HCl

L21 ANSWER 7 OF 7 USPAT2 on STN
AN 2004:321719 USPAT2
TI Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases
IN Jones, Stuart Donald, Macclesfield, UNITED KINGDOM
Sall, Daniel Jon, Greenwood, IN, UNITED STATES
Wiley, Michael Robert, Indianapolis, IN, UNITED STATES
PA Eli Lilly and Company, Indianapolis, IN, UNITED STATES (U.S. corporation)
PI US------7115609 B2 20061003
WO--2003050109 20030619
AI 2002US-000496019 20021209 (10)
2002WO-US0037595 20021209
20040601 PCT 371 date
PRAI 2001US-000339325P 20011212 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Bernhardt, Emily
LREP Jackson, Thomas E.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1,14
DRWN No Drawings
LN.CNT 1746
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I)

##STR1## in which R.sup.1, R.sup.2, n and X.sup.1 have the meanings given in the specification are Factor Xa inhibitors useful in the treatment of thrombotic disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 544478-85-5P 544478-86-6P
(preparation of alanylpiperidine heterocyclic derivs. as factor Xa inhibitors for use in treatment of thrombotic disorders)
RN 544478-85-5 USPAT2
CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R)-1-(cyclohexylmethyl)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 544478-86-6 USPAT2
CN 1H-Indole-6-carboxamide, N-[(1R)-1-(cyclohexylmethyl)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-, hydrochloride (10:11) (CA INDEX NAME)

Absolute stereochemistry.

L21 ANSWER 7 OF 7 USPAT2 on STN (Continued)



●11/10 HCl

```
=> d his

     FILE 'HCAPLUS' ENTERED AT 13:00:41 ON 18 NOV 2008
L1             1 US20060106030 /PN

     FILE 'REGISTRY' ENTERED AT 13:00:50 ON 18 NOV 2008

     FILE 'HCAPLUS' ENTERED AT 13:00:50 ON 18 NOV 2008
L2             TRA L1 1- RN :       46 TERMS

     FILE 'REGISTRY' ENTERED AT 13:00:51 ON 18 NOV 2008
L3            46 SEA L2
                 ACT J594C1Q1/Q
L4               STR
L5               STR L4
L6             1 L5
L7       1386111 NC2NC2/ES
L8             1 L5 SAM SUB=L7
L9            12 L5 FULL SUB=L7
L10            0 L9 AND L3
L11           41 L3 AND NC2NC2/ES
L12            1 L11 AND NC4-C6/ES
L13              STR L5
L14            1 L13
L15            1 L13 SAM SUB=L7
L16            9 L13 FULL SUB=L7
L17           21 L9,L16
                 SAV TEM J594C1/A L17
L18            0 L17 AND L3

     FILE 'HCAOLD' ENTERED AT 13:57:24 ON 18 NOV 2008
L19            0 L17

     FILE 'HCAPLUS' ENTERED AT 13:57:28 ON 18 NOV 2008
L20            5 L17

     FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 14:01:25 ON 18 NOV 2008
L21            7 L17

=>
```